Literature DB >> 20859426

How I treat mantle cell lymphoma.

David J Straus.   

Abstract

Entities:  

Year:  2007        PMID： 20859426      PMCID： PMC2793846          DOI： 10.1200/JOP.0758501

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  16 in total

1.  Mantle cell lymphoma: a clinicopathologic study of 80 cases.

Authors:  L H Argatoff; J M Connors; R J Klasa; D E Horsman; R D Gascoyne
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

2.  Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT).

Authors:  Benjamin D Rosenbluth; Joachim Yahalom
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-06       Impact factor: 7.038

3.  Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

Authors:  F Bosch; A López-Guillermo; E Campo; J M Ribera; E Conde; M A Piris; T Vallespí; S Woessner; E Montserrat
Journal:  Cancer       Date:  1998-02-01       Impact factor: 6.860

4.  High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.

Authors:  A S Freedman; D Neuberg; J G Gribben; P Mauch; R J Soiffer; D C Fisher; K C Anderson; N Andersen; R Schlossman; M Kroon; J Ritz; J Aster; L M Nadler
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

5.  High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.

Authors:  Ajay K Gopal; Joseph G Rajendran; Stephen H Petersdorf; David G Maloney; Janet F Eary; Brent L Wood; Theodore A Gooley; Sharon A Bush; Lawrence D Durack; Paul J Martin; Dana C Matthews; Frederick R Appelbaum; Irwin D Bernstein; Oliver W Press
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

6.  Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries.

Authors:  Elisabeth Vandenberghe; Carmen Ruiz de Elvira; Fausto R Loberiza; E Conde; A López-Guillermo; C Gisselbrecht; F Guilhot; Julie M Vose; Koen van Biesen; J Douglas Rizzo; Dennis D Weisenburger; Peter Isaacson; Mary M Horowitz; Anthony H Goldstone; Hillard M Lazarus; Norbert Schmitz
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

7.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

Authors:  J O Armitage; D D Weisenburger
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

8.  Limited-stage mantle-cell lymphoma.

Authors:  H A Leitch; R D Gascoyne; M Chhanabhai; N J Voss; R Klasa; J M Connors
Journal:  Ann Oncol       Date:  2003-10       Impact factor: 32.976

9.  The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Authors:  Roswitha Forstpointner; Martin Dreyling; Roland Repp; Sandra Hermann; Annette Hänel; Bernd Metzner; Christiane Pott; Frank Hartmann; Frank Rothmann; Robert Rohrberg; Hans-Peter Böck; Hannes Wandt; Michael Unterhalt; Wolfgang Hiddemann
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

10.  Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.

Authors:  Hannes Kaufmann; Markus Raderer; Stefan Wöhrer; Andreas Püspök; Alexander Bankier; Christoph Zielinski; Andreas Chott; Johannes Drach
Journal:  Blood       Date:  2004-05-27       Impact factor: 22.113
View more
  1 in total

1.  Nasopharyngeal Mantle Cell Lymphoma: An Extremely Rare Entity.

Authors:  Mark Paul; Najihah Hanim Asmi; Eshamsol Kamar Omar; Suhaila Abdullah; Irfan Mohamad
Journal:  Oman Med J       Date:  2019-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.